 | ||
How to make gcmaf at home
GcMAF (or Gc protein-derived macrophage activating factor) is a protein produced by modification of vitamin D-binding protein. Proponents of GcMAF claim that it is an immunomodulatory protein that has antitumor properties and strengthens the immune system by macrophage activation. Organizations including Cancer Research UK have issued warnings informing the public that there is no reliable evidence that GcMAF is effective.
Contents
Gcmaf for the treatment of cancer autism viral and bacterial disease
Description
Biochemically, GcMAF results from sequential deglycosylation of the vitamin D-binding protein (the Gc protein), which is naturally promoted by lymphocytes (B and T cells). The resulting protein may be a macrophage activating factor (MAF). MAFs are lymphokines that control the expression of antigens on the surface of macrophages, and one of their functions is to make macrophages become cytotoxic to tumors.
Controversies
In 2008 claims were made that GcMAF can provide a permanent cure for cancer and HIV by activating macrophage white blood cell production. These claims have been the subject of criticism. The papers supporting the claims have since been retracted by the journals in which they were published. Consumers have been warned about illegal marketing of the substance over the internet. The Belgian Anticancer Fund has communicated serious concerns to other journals that published studies on GcMAF by Yamamoto and colleagues.
GcMAF has been promoted as a cure for cancer, HIV, autism and other conditions. The integrity of the research, conducted by Nobuto Yamamoto and colleagues, that originally prompted claims regarding cancer and HIV has been questioned. Cancer Research UK has warned the public about spurious claims of clinical benefits, misleadingly based on reduced levels of the alpha-N-acetylgalactosaminidase enzyme (also known as nagalase), whose production might be increased in many cancers. Nagalase is an enzyme present in normal cells and its use to diagnose or follow-up the diseases claimed to be cured by GcMAF has not been validated. Nagalase deficiency, however, is associated to a rare congenital metabolic disorder called Schindler/Kanzaki disease.
Three out of four of the original studies authored by Yamamoto (published between 2007 and 2009) were retracted by the scientific journals in which they were published in 2014, officially due to irregularities in the way ethical approval was granted. Retraction reasons also included methodological errors in the studies.
Other publications
A Japanese clinic reported its experience with three patients out of a total of 345 patients they treated with GcMAF in combination with other alternative therapies, this report was published in 2013, and concluded that observations were "hopeful".
They also published a case report that described the case of a breast cancer patient treated with GcMAF, other alternative therapies and standard of care (exemestane), the evolution was favorable.
Other controversial researches on GcMAF have been published in what are known as predatory journals.